GSK, Sanofi and Merck Seek Further Inroads In India Industry
This article was originally published in PharmAsia News
Executive SummaryThe strictly local pharmaceutical industry in India is expected to shrink this year as at least three companies consider international deals. U.K.-based GlaxoSmithKline is said to be interested in Piramal Healthcare, while Sanofi-Aventis of France and Merck KGaA of Germany consider other ties. GSK already had tipped its hand when it said it was stepping up its focus on emerging markets. Merck said it was interested in signing an Indian deal later this year as it negotiates other local ties, including at least two acquisitions. (Click here for more
You may also be interested in...
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.